Legal status · United States
Is NNC0165-1875 legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. NNC0165-1875 is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 3 human studies are cited on its profile.
NNC0165-1875 in the United States at a glance
| Classification | Investigational, not approved |
|---|---|
| Note | Phase 2 completed as an add-on to semaglutide. No approval anywhere. |
| FDA approval status | Investigational. Not approved. Phase 2 completed with a result its own authors describe as not clinically meaningful. |
| Human studies cited | 3 of 3 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the NNC0165-1875 profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
NNC0165-1875 is being studied in registered clinical trials but has not received FDA marketing approval in the United States.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What NNC0165-1875 is
The clearest test of stacking a second appetite hormone onto semaglutide, and it failed on both counts. The authors call the added effect modest and not clinically meaningful, and the higher dose was not tolerated.
Peptide YY is the gut hormone that tells your brain the meal is over, acting through a different receptor from GLP-1. On paper it is the obvious partner: two independent satiety pathways should add up.
Mechanism: A long-acting analogue of PYY(3-36), the truncated form of peptide YY released from L cells in the distal gut after eating. PYY(3-36) is selective for the Y2 receptor, which is presynaptic and inhibitory on hypothalamic neuropeptide Y neurons, reducing the orexigenic drive.
Regulatory history: Investigational. Not approved. Phase 2 completed with a result its own authors describe as not clinically meaningful.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for NNC0165-1875 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
NNC0165-1875 in other countries
Frequently asked questions
Is NNC0165-1875 legal in the United States?
No. NNC0165-1875 is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 3 human studies are cited on its profile. Note: Phase 2 completed as an add-on to semaglutide. No approval anywhere.
Can I buy NNC0165-1875 in the United States?
No approved product exists to buy. In the United States NNC0165-1875 is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: Phase 2 completed as an add-on to semaglutide. No approval anywhere.
Is NNC0165-1875 FDA approved?
No. FDA status: Investigational. Not approved. Phase 2 completed with a result its own authors describe as not clinically meaningful.. Current US classification: "Investigational, not approved". On the evidence, 3 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for NNC0165-1875 live on its compound profile.
NNC0165-1875 profileThis page is general information about the regulatory status of NNC0165-1875 in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.